Advertisement
REGN vs VRTX
Which Stock Would AI Choose? Regeneron Pharmaceuticals (REGN) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- REGN trades at a comparatively low price-to-earnings (P/E) multiple of roughly 16–17x, reflecting investor concerns about growing competition for its Eylea eye-care franchise.
- VRTX carries a premium valuation supported by a dominant cystic fibrosis (CF) franchise and an expanding pipeline into pain, gene therapy, and kidney disease.
- Regeneron recently expanded its two-decade Sanofi alliance in a deal worth up to $8 billion, while Vertex is diversifying through its pending Crinetics Pharmaceuticals acquisition.
- Both companies generate substantial cash flow, but REGN's earnings are more diversified across immunology, ophthalmology, and oncology, whereas VRTX remains more concentrated in CF.
- Relative performance has diverged in recent weeks: REGN has pulled back from recent highs, while VRTX has been steadier after raising full-year revenue guidance.
Introduction
Regeneron Pharmaceuticals and Vertex Pharmaceuticals are two of the largest and most profitable biotechnology companies in the market, yet they present very different profiles for investors. Both are widely followed by institutional investors and retail traders alike, which makes a direct stock comparison valuable for anyone weighing large-cap biotech exposure. Regeneron's strength lies in a diversified portfolio spanning immunology, ophthalmology, and oncology, while Vertex has built a near-monopoly in cystic fibrosis and is now betting on new therapeutic categories. This comparison examines recent performance, growth drivers, and market positioning to help readers understand how these two names stack up in the current environment.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals is a Tarrytown, New York-based biotechnology company best known for blockbuster products including Dupixent (shared with Sanofi), the Eylea family of retinal disease treatments, and the oncology therapy Libtayo. In recent market activity, REGN shares have pulled back from their 52-week highs, with the stock trading down on a year-to-date basis despite solid fundamental results. First-quarter revenue grew roughly 19% year over year, driven by higher Dupixent profit-sharing and Eylea HD sales, while adjusted earnings per share (EPS) topped consensus estimates.
Sentiment has been shaped by two opposing forces. On the positive side, the company expanded its long-running Sanofi alliance in a deal that provides $1 billion upfront and up to $7 billion in potential milestones for next-generation immunology candidates. On the negative side, investors have focused on declining legacy Eylea sales amid competition from Roche's Vabysmo, as well as mixed late-stage oncology data. This tension has left the stock trading below recent highs even as analysts maintain generally constructive price targets.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals is a Boston-based biotechnology company that dominates the cystic fibrosis market through its CFTR modulator portfolio, led by Trikafta/Kaftrio and the newer once-daily therapy Alyftrek. The company is actively diversifying into non-opioid pain management with Journavx, gene editing with Casgevy, and kidney disease through its povetacicept program. In recent quarters, VRTX has delivered steady revenue growth, reporting an 8% year-over-year increase in the first quarter followed by a stronger 12% increase in the second quarter, when it also raised its full-year revenue guidance to a range of $13.10–$13.20 billion.
Investor attention has centered on how quickly newer products can reduce reliance on the CF franchise. Alyftrek has surpassed $1 billion in cumulative sales, while Journavx prescription volumes and Casgevy patient starts have accelerated. The pending acquisition of Crinetics Pharmaceuticals, focused on endocrinology, further underscores Vertex's diversification strategy. This progress has supported relatively resilient share performance, even as a maturing CF base and competitive threats remain areas of analyst scrutiny.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page showcases a curated selection of AI trading bots. Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and statistical profile. Because no single bot fits every market condition, only the best-performing and most suitable bots for the current environment earn a place in this featured section. Whether you are evaluating biotech names like REGN and VRTX or scanning the broader market, exploring the Trending AI Robots can help you identify automated strategies aligned with today's conditions.
Head-to-Head Comparison
The clearest contrast between these two companies is revenue concentration. Regeneron's earnings are spread across Dupixent, Eylea, and Libtayo, giving it a broader base but also exposing it to competitive pressure in ophthalmology and ongoing patent litigation risk. Vertex remains heavily dependent on cystic fibrosis, yet that franchise enjoys durable pricing power and limited direct competition, which supports higher profit margins and a richer valuation multiple.
Growth profiles also differ. Regeneron is defending and transitioning its Eylea franchise while leaning on the fast-growing Dupixent and its deep pipeline in oncology and genetic medicines. Vertex, by contrast, is building entirely new franchises from a dominant cash-generating core, with Journavx, Casgevy, and its nephrology pipeline still early in their commercial ramp. On valuation, REGN's modest P/E multiple suggests the market is discounting near-term uncertainty, whereas VRTX's premium reflects confidence in its competitive moat. Sector exposure is similar—both are large-cap biotechnology—but their risk factors diverge: REGN faces biosimilar and competitive erosion, while VRTX faces pipeline execution and diversification risk.
Tickeron AI Verdict
Based on observable trend consistency, stability, and relative positioning, Tickeron's AI framework would likely lean toward VRTX in the current environment. Vertex's steadier price behavior, upwardly revised guidance, and expanding pipeline provide a more consistent trend profile than Regeneron's recent pullback and competitive headwinds. That said, REGN's discounted valuation and catalyst-rich pipeline could appeal to a momentum-reversal or value-oriented model. The relative edge is narrow and probabilistic rather than definitive, and it could shift as new clinical data and earnings reports emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a Hold and VRTX is a Hold.
REGN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for REGN turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 33 of 49 cases over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where REGN's RSI Indicator exited the oversold zone, 18 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 57 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
Following a +5.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 207 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
REGN moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for REGN crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
REGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.539) is normal, around the industry mean (2.978). P/E Ratio (18.678) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.005) settles around the average of (134.267) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (438.009).
Momentum Indicator for VRTX turns negative, indicating new downward trend
VRTX saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In 45 of the 87 cases, the stock moved further down in the following days. The odds of a decline are at 52%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for VRTX turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 60 similar instances when the indicator turned negative. In 30 of the 60 cases the stock turned lower in the days that followed. This puts the odds of success at 50%.
VRTX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VRTX crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
The Aroon Indicator for VRTX entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VRTX's RSI Oscillator exited the oversold zone, 11 of 14 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 36 of 54 cases where VRTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
Following a +4.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRTX advanced for three days, in 238 of 368 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
VRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 19 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. VRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.283) is normal, around the industry mean (2.978). P/E Ratio (28.998) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (1.939) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (10.449) is also within normal values, averaging (438.009).
REGN | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 86 | 19 | |
SMR RATING 1..100 | 59 | 41 | |
PRICE GROWTH RATING 1..100 | 50 | 46 | |
P/E GROWTH RATING 1..100 | 16 | 43 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (88) in the Biotechnology industry is in the same range as VRTX (91). This means that REGN’s stock grew similarly to VRTX’s over the last 12 months.
VRTX's Profit vs Risk Rating (19) in the Biotechnology industry is significantly better than the same rating for REGN (86). This means that VRTX’s stock grew significantly faster than REGN’s over the last 12 months.
VRTX's SMR Rating (41) in the Biotechnology industry is in the same range as REGN (59). This means that VRTX’s stock grew similarly to REGN’s over the last 12 months.
VRTX's Price Growth Rating (46) in the Biotechnology industry is in the same range as REGN (50). This means that VRTX’s stock grew similarly to REGN’s over the last 12 months.
REGN's P/E Growth Rating (16) in the Biotechnology industry is in the same range as VRTX (43). This means that REGN’s stock grew similarly to VRTX’s over the last 12 months.
| REGN | VRTX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 67% | 1 day ago 79% |
| Stochastic ODDS (%) | 1 day ago 61% | 1 day ago 67% |
| Momentum ODDS (%) | 1 day ago 61% | 1 day ago 52% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 50% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 41% |
| TrendMonth ODDS (%) | 1 day ago 62% | 1 day ago 35% |
| Advances ODDS (%) | 5 days ago 65% | 5 days ago 65% |
| Declines ODDS (%) | 1 day ago 56% | 7 days ago 42% |
| BollingerBands ODDS (%) | 1 day ago 60% | 1 day ago 75% |
| Aroon ODDS (%) | 1 day ago 68% | 1 day ago 41% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
REGN’s FA Score shows that 1 FA rating(s) are green while VRTX’s FA Score has 1 green FA rating(s).
- REGN’s FA Score: 1 green, 4 red.
- VRTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
REGN’s TA Score shows that 4 TA indicator(s) are bullish while VRTX’s TA Score has 4 bullish TA indicator(s).
- REGN’s TA Score: 4 bullish, 6 bearish.
- VRTX’s TA Score: 4 bullish, 6 bearish.
Price Growth
REGN (@Biotechnology) experienced а +2.52% price change this week, while VRTX (@Biotechnology) price change was -1.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.86%. For the same industry, the average monthly price growth was -18.66%, and the average quarterly price growth was -19.56%.
Reported Earning Dates
REGN is expected to report earnings on Oct 30, 2026.
VRTX is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Biotechnology (-7.86% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
REGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with VRTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then VRTX could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | -1.10% | ||
| VRTX - REGN | 43% Loosely correlated | +0.44% | ||
| RPRX - REGN | 36% Loosely correlated | -1.13% | ||
| BMRN - REGN | 36% Loosely correlated | -0.02% | ||
| ARQT - REGN | 36% Loosely correlated | +10.65% | ||
| INCY - REGN | 33% Loosely correlated | +0.16% | ||
More | ||||
VRTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with RPRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then RPRX could also see price increases.
| Ticker / NAME | Correlation To VRTX | 1D Price Change % | ||
|---|---|---|---|---|
| VRTX | 100% | +0.44% | ||
| RPRX - VRTX | 45% Loosely correlated | -1.13% | ||
| EDIT - VRTX | 44% Loosely correlated | +2.98% | ||
| INCY - VRTX | 44% Loosely correlated | +0.16% | ||
| BMRN - VRTX | 43% Loosely correlated | -0.02% | ||
| HALO - VRTX | 40% Loosely correlated | +0.54% | ||
More | ||||